Publications by authors named "Nadezhda Rudometova"
Although mRNA vaccines encapsulated in lipid nanoparticles (LNPs) have demonstrated a safety profile with minimal serious adverse events in clinical trials, there is opportunity to further reduce mRNA reactogenicity. The development of naked mRNA vaccines could improve vaccine tolerability. Naked nucleic acid delivery using the jet injection method may be a solution.
View Article and Find Full Text PDFArticle Synopsis
- The H5N8 avian influenza virus poses a risk to bird populations and potential human health concerns, necessitating the development of a safe and effective vaccine.
- Researchers created an experimental pVAX-H5 DNA vaccine that encodes a modified version of the virus's hemagglutinin and tested it on mice, resulting in a strong antibody and T-cell response.
- Both liquid and lyophilized versions of the pVAX-H5 vaccine provided complete protection for mice against lethal influenza A virus challenges, showing promise as a candidate for combating H5N8.
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus.
View Article and Find Full Text PDFQuick label-free virus screening and highly sensitive analytical tools/techniques are becoming extremely important in a pandemic. In this study, we developed a biosensing device based on the silicon nanoribbon multichannel and dielectrophoretic controlled sensors functionalized with SARS-CoV-2 spike antibodies for the use as a platform for the detection and studding of properties of viruses and their protein components. Replicatively defective viral particles based on vesicular stomatitis viruses and HIV-1 were used as carrier molecules to deliver the target SARS-CoV-2 spike S-proteins to sensory elements.
View Article and Find Full Text PDFArticle Synopsis
- Researchers tested the antiviral effectiveness of Arbidol (Umifenovir) against SARS-CoV-2 using a simulated viral system with the virus's spike protein.
- The study identified multiple binding sites for Arbidol on the spike protein and noted that Arbidol's binding affects the protein's structural flexibility and interaction with enzymes.
- The findings suggest that Arbidol can bind to various parts of the spike protein, contributing to its antiviral properties, which could aid in developing effective treatments targeting the virus's entry into cells.
When developing drugs against SARS-CoV-2, it is important to consider the characteristics of patients with different co-morbidities. People infected with HIV-1 are a particularly vulnerable group, as they may be at a higher risk than the general population of contracting COVID-19 with clinical complications. For such patients, drugs with a broad spectrum of antiviral activity are of paramount importance.
View Article and Find Full Text PDFNucleic acid-based influenza vaccines are a promising platform that have recently and rapidly developed. We previously demonstrated the immunogenicity of DNA vaccines encoding artificial immunogens AgH1, AgH3, and AgM2, which contained conserved fragments of the hemagglutinin stem of two subtypes of influenza A-H1N1 and H3N2-and conserved protein M2. Thus, the aim of this study was to design and characterize modified mRNA obtained using the above plasmid DNA vaccines as a template.
View Article and Find Full Text PDFThe analysis of a gene fragment encoding protease and part of reverse transcriptase was carried out for 55 sera collected in 2016 and 2018 from HIV-1-infected patients diagnosed in 2014-2018 living in the south of Western Siberia, Russia: Altai Territory ( = 11), Republic of Altai ( = 15), Kemerovo region ( = 18), and Novosibirsk region ( = 11). CRF63_02A was the dominant genetic form (>70%) in the Altai Territory and Kemerovo and Novosibirsk regions, with subsubtype A6 comprising <30% of samples. In the Altai Republic, subsubtype A6 was predominant (53%), with 33% of viruses belonging to CRF63_02A.
View Article and Find Full Text PDFOne of the key stages in the development of mRNA vaccines is their delivery. Along with liposome, other materials are being developed for mRNA delivery that can ensure both the safety and effectiveness of the vaccine, and also facilitate its storage and transportation. In this study, we investigated the polyglucin:spermidine conjugate as a carrier of an mRNA-RBD vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
View Article and Find Full Text PDFArticle Synopsis
- The article discusses the creation of an artificial protein called nTBI that could be used as a vaccine against HIV-1 by incorporating specific B-cell and T-cell epitopes.
- The nTBI protein is a modified version of an earlier design (TBI), with some epitopes swapped to enhance the response from broadly neutralizing antibodies against HIV-1.
- Immunization studies in rabbits showed that the nTBI protein effectively stimulated the production of antibodies that can recognize and neutralize the HIV-1 virus.